Premium
Translational Science
Author(s) -
Marianna Volpert,
Brian Wan-Chi Tse,
Ellca Ratther,
Nataly Stylianou,
Mannan Nouri,
Mani Roshan-Moniri,
Miriam Butler,
Josselin Caradec,
Cheryl Y. GregoryEvans,
Melanie Lehman,
Mandeep Takhar,
Nicholas Erho,
Mohamed Alshalafa,
Elai Davicioni,
Robert B. Jenkins,
R. Jeffrey Karnes,
Robert B. Den,
Ladan Fazli,
Martin Gleave,
Elizabeth D. Williams,
Paul S. Rennie,
Ralph Buttyan,
Jennifer H. Gunter,
Pamela J. Russell,
Colleen C. Nelson,
Brett G. Hollier
Publication year - 2016
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/bju.13567
Subject(s) - citation , library science , translational science , translational research , computer science , medicine , pathology
Hospital, Translational Research Institute, Brisbane, Queensland, Australia; 2Minomic International Ltd, Sydney, New South Wales, Australia Aim: To assess clinical utility of MIL-38 monoclonal antibody (previously called BLCA-38a), which binds to a surface protein, glypican-1 (GPC-1), on prostate cancer (PCa) but not normal prostate cellsa. Minomic International Ltd has shown that MIL-38 could detect PCa cells in urine from patients, distinguishing PCa from benign prostate hypertrophy (BPH) with high sensitivity and specificity. We are currently testing the functional role of GPC-1 in PCa growth, invasion and metastases, and its potential for imaging PCa